Since the Hungarian oncological protocols usually incorporate the results of novel discoveries, target- and immunotherapeutic agents were also introduced into the treatment of melanoma: the BRAF inhibitor vemurafenib was officially registered in 2012, and the CTLA4 inhibitor ipilimumab was accepted in 2011, while the PD1 inhibitors nivolumab and pembrolizumab were accepted in 2015. Here, CTLA4 is linked to melanoma.